Halberd Eradicates Another Inflammatory Cytokine Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board certified attending neurologist, stated, "Interleukin-12's pro-inflammatory action appears to increase deleterious pathologic effects by phosphorylated tau and Tumor Necrosis Factor-alpha (TNF-alpha). These effects have been strongly associated with Alzheimer's Disease and other neurodegenerative diseases."
William A. Hartman, Halberd Corporation's Chairman, President & CEO, added, "We have now demonstrated that we can eradicate targeted disease antigens and inflammatory cytokines associated with neurodegenerative diseases. We have no doubt that our technology will also be successful in eliminating the balance of the targeted antigens identified in our test plan."
Halberd’s Scheduled Testing
Proof of Eradication from CSF Results
| Associated Antigens
(Top 10 | PTSD/CTE | Neurodegenerative Diseases* |
| Phosphorylated Tau | Completed | Completed |
| IL-6 | Completed | Completed |
| TNF-α | Completed | Completed |
| IL-1 | N/A | Completed |
| IL-12 | N/A | Completed |
| Beta Amyloid | N/A | 4Q21 |
| IL-2 | N/A | 4Q21 |
| IL-4 | N/A | 4Q21 |
| Tau | N/A | 1Q22 |
| Glutamate | 1Q22 | 1Q22 |
N/A – indicates antigen is not associated with listed condition.
* -- Includes Alzheimer’s, Parkinson’s, Epilepsy & Lou Gehrig’s Diseases
Hartman continued, "Once our test plan is completed, we intend to promote our technology to organizations and entities with an expressed interest in the treatment of Traumatic Brain Injury (TBI), PTSD/CTE, and other neurodegenerative diseases. Halberd's advancement in the elimination of the pathogens listed above is unique in the world. Our goal is to create a revolution in the successful treatment of the causes of neurodegenerative diseases that heretofore have been considered incurable."
https://www.newsfilecorp.com/release/107666